Logo Prima Biomed


Welcome to the Newsroom

26 June 2017

Operational Update


ENGLISH

 

SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD), has provided an update on the Company’s two active clinical trials in IMP321. Prima is pleased to advise that clinical studies of IMP321 are progressing well.

 

(...)